SEARCH

SEARCH BY CITATION

Keywords:

  • aminoacyl-tRNA synthetase;
  • amber suppressor tRNA;
  • interleukin-8;
  • azido group;
  • site-specific protein modification

Abstract

  1. Top of page
  2. Abstract
  3. Introduction
  4. Results
  5. Discussion
  6. Materials and Methods
  7. Acknowledgements
  8. References

Insect cells are useful for the high-yield production of recombinant proteins including chemokines and membrane proteins. In this study, we developed an insect cell-based system for incorporating non-natural amino acids into proteins at specific sites. Three types of promoter systems were constructed, and their efficiencies were compared for the expression of the prokaryotic amber suppressor tRNATyr in Drosophila melanogaster Schneider 2 cells. When paired with a variant of Escherichia coli tyrosyl-tRNA synthetase specific for 3-iodo-L-tyrosine, the suppressor tRNA transcribed from the U6 promoter most efficiently incorporated the amino acid into proteins in the cells. The transient and stable introductions of these prokaryotic molecules into the insect cells were then compared in terms of the yield of proteins containing non-natural amino acids, and the “transient” method generated a sevenfold higher yield. By this method, 4-azido-L-phenylalanine was incorporated into human interleukin-8 at a specific site. The yield of the azido-containing IL-8 was 1 μg/1 mL cell culture, and the recombinant protein was successfully labeled with a fluorescent probe by the Staudinger–Bertozzi reaction.

Introduction

  1. Top of page
  2. Abstract
  3. Introduction
  4. Results
  5. Discussion
  6. Materials and Methods
  7. Acknowledgements
  8. References

The repertoire of genetically encoded amino acids has been expanded in Escherichia coli,1 mammalian cells,2 and yeast,3 for the purpose of increasing the chemical and structural diversity of proteins. These developments have enabled the cell-based production of proteins with “non-natural” amino acids at specific sites, called “alloproteins”.4 These amino acids have novel structures not found in the canonical amino acids, such as a heavy atom,2, 5 a fluorescent probe,6 photo-induced crosslinkers,7, 8 chemical “handles” for site-specific protein modification,9–11 bulky groups tethered with a long linker,11, 12 a hydroxyl group in place of the α-amino group,13, 14 and naturally occurring post-translational modifications.15, 16 The incorporation of these unique functionalities facilitates protein science and engineering.

Non-natural amino acids have not been genetically encoded in insect cells, although these cells are widely used for the large-scale preparation of recombinant proteins. Insect cells are useful for producing such proteins that cannot be expressed in E. coli and yeast cells, and are difficult to produce in large amounts in mammalian cells. A variety of cell lines have been developed from different insect sources. The Sf9 cell line from Spodoptera frugiperda and the HighFive cell line from Trichoplusia ni have been successfully used to prepare mammalian proteins, including G protein-coupled receptors,17 whereas Drosophila melanogaster Schneider 2 cells (S2 cells) have been used for the preparation of secreted proteins with sugar chains, including human cytokines18 and antibodies.19

The genetic encoding of a non-natural amino acid relies on the pair of an amber suppressor tRNA and a variant of the aminoacyl-tRNA synthetase (aaRS) specific to the amino acid. This aaRS–tRNA pair must not crossreact with any endogenous tRNA or aaRS species; otherwise, the non-natural amino acid would be incorporated at other sites in addition to the amber codon, while the amber codon would also be translated into canonical amino acids. This required “orthogonality” of the aaRS–tRNA pair to the host translation system has been achieved by using exogenous aaRS–tRNA pairs.1, 2, 20 For example, 3-iodo-L-tyrosine (Fig. 1) has been genetically encoded in mammalian cells with the pair of a specific variant of tyrosyl-tRNA synthetase (TyrRS) from E. coli and the amber suppressor tRNATyr from Bacillus stearothermophilus.2

Figure 1. Chemical structures of L-tyrosine and its derivatives.

Download figure to PowerPoint

thumbnail image

Such aaRS variants, like other recombinant proteins, can be expressed using conventional expression vectors, while the expression of prokaryotic tRNA species in mammalian or yeast cells requires the development of appropriate systems.2, 12, 21, 22 Although the suppressor tRNAs from D. melanogaster23, 24 and Schizosaccharomyces pombe25 reportedly caused nonsense suppression in insect cells, prokaryotic tRNAs have not been expressed in these cells. To develop an expression system, the following two factors must be considered. One is the internal promoter within a tRNA gene, which works to transcribe the gene in eukaryotic cells and is absent from most of the prokaryotic tRNA genes. The B. stearothermophilus amber suppressor tRNATyr has been successfully utilized in mammalian cells,2, 26, 27 because this tRNA happens to have the internal promoter sequence.

Another factor is the sequence at the 5′ side of the tRNA coding sequence. Three types of such upstream sequences have been used for prokaryotic tRNA expression. One is the upstream sequence of a human tRNATyr gene, which was connected to the B. stearothermophilus suppressor tRNATyr gene to enhance its expression in mammalian cells.2 The second type is the H1 and U6 promoters, which were originally located upstream of RNA coding sequences, and have been placed before the genes encoding E. coli tRNATyr, tRNALeu, and archaeal tRNAPyl, to achieve their efficient expression in eukaryotic cells.12, 21 Note that these tRNA species all lack the internal promoter. The third type includes a eukaryotic tRNA sequence with the internal promoter12 and the internal promoter sequences isolated from the small nucleolar RNA and RNase-P RNA genes. These sequences have also been placed before the prokaryotic tRNA genes lacking the internal promoter, to facilitate their expression in eukaryotic cells.22

In this study, we tested different systems for expressing a prokaryotic amber suppressor tRNA in D. melanogaster S2 cells. The E. coli suppressor tRNATyr transcribed from the U6 promoter generated the highest yield of alloproteins, although the B. stearothermophilus tRNATyr was also useful in the insect cells. The E. coli TyrRS–suppressor tRNATyr pair was shown to be orthogonal to the insect aaRS–tRNA system, and 3-iodo-L-tyrosine and 4-azido-L-phenylalanine (Fig. 1) were successfully incorporated into the proteins produced by cells transiently transfected with the plasmids. The feasibility of stably maintaining the genetic system for encoding non-natural amino acids was also demonstrated with S2 cells.

Results

  1. Top of page
  2. Abstract
  3. Introduction
  4. Results
  5. Discussion
  6. Materials and Methods
  7. Acknowledgements
  8. References

Development of an expression system for prokaryotic amber suppressor tRNA in S2 cells

We developed an expression system for a prokaryotic suppressor tRNA, by monitoring the site-specific incorporation of 3-iodo-L-tyrosine into proteins, using the tRNA and a TyrRS variant. This non-natural amino acid has been incorporated in mammalian cells expressing the B. stearothermophilus suppressor tRNATyr and a 3-iodo-L-tyrosine-specific variant of E. coli TyrRS,28 designated as iodoTyrRS-ec. We tested this pair in D. melanogaster S2 cells with the following two modifications. First, instead of using iodoTyrRS-ec, we used another variant, designated as iodoTyrRS-ed,29 which is derived from the former enzyme and shows greatly improved specificity for 3-iodo-L-tyrosine. Second, the upstream sequence connected to the prokaryotic tRNA gene was changed from that of the human tRNATyr gene to that of the D. melanogaster tRNATyr gene23 [Fig. 2(A)]. The lacZ gene with an amber mutation at position 91, lacZ(Am91), was used to detect the amber suppression, with 3-iodo-L-tyrosine (1 mM) supplementation of the growth media. The genes encoding the suppressor tRNA, iodoTyrRS-ed, and LacZ(Am91), each carried by a different vector, were transiently introduced into S2 cells. The amber suppression occurred at an efficiency of 1% relative to the yield of the wild-type LacZ in S2 cells [Fig. 2(B)]. The removal of 3-iodo-L-tyrosine from the growth media abolished the amber suppression (data not shown), indicating that this non-natural amino acid was incorporated at the amber position.

Figure 2. Development of the expression system for prokaryotic suppressor tRNATyr in S2 cells. A: The three expression systems for the bacterial suppressor tRNATyr molecules. “Dm” means D. melanogaster. “TTTTT” indicates the transcription terminator. B: The relative amber suppression efficiencies of the three expression systems, measured in terms of the β-gal activity in the transiently transfected S2 cells. The bar above “vector” shows the β-gal activity with neither LacZ(Am91), iodoTyrRS-ed, nor suppressor tRNATyr. The bar above “–tRNA” shows the β-gal activity without suppressor tRNATyr. The white bar shows 5% of the β-gal activity due to the wild-type LacZ transiently expressed in the cells. C: A map of the plasmid pAcEYR/iodoTyrRS-ed. D: The amber suppression due to the U6 promoter system for expressing the E. coli suppressor tRNATyr. “–tRNA,” “–aaRS,” and “–IY” mean the absence of the suppressor tRNATyr, iodoTyrRS-ed, and 3-iodo-L-tyrosine, respectively. Each bar represents the average of three independent experiments throughout this figure.

Download figure to PowerPoint

thumbnail image

This finding showed that the B. stearothermophilus tRNATyr gene is useful for genetically encoding non-natural amino acids in not only mammalian cells but also insect cells. We then tested another strategy involving external promoters, to explore the possibility of improving the suppression efficiency. We constructed two more gene constructs, each including the E. coli amber suppressor tRNATyr gene instead of the B. stearothermophilus tRNATyr gene, because the internal promoter in the bacillus tRNA gene may interfere with the transcription from external promoters [Fig. 2(A)]. The first construct contained the D. melanogaster U6-2 promoter, which was previously used for the expression of short hairpin RNA in S2 cells,30 placed at the 5′ end of the E. coli suppressor tRNATyr sequence. This construct, designated as U6-EYR, efficiently caused amber suppression, and the yield of the suppression product of lacZ(Am91) was 6% of that of the wild-type LacZ, in terms of the β-galactosidase activity [Fig. 2(B)]. The second construct consisted of a tRNATyr gene from D. melanogaster, together with its upstream sequence, and the E. coli tRNATyr sequence. These two regions were separated by a short linker sequence. The fly tRNA gene was found to allow very little expression of the downstream E. coli tRNATyr gene [Fig. 2(B)].

Since U6-EYR worked best among the tested constructs, to optimize the suppression efficiency, three copies of U6-EYR were carried in tandem on a vector and used to produce alloproteins. We previously reported that the alloproteins yield was improved by increasing the copy number of the suppressor tRNA gene.2, 12 The suppression efficiency due to three copies of U6-EYR was found to be 1.8-fold greater than that due to one copy, in terms of the β-galactosidase activity.

Finally, we examined the orthogonality of the iodoTyrRS-ed and E. coli suppressor tRNATyr pair in S2 cells. Three copies of U6-EYR and the iodoTyrRS-ed gene were cloned in the same plasmid, pAcEYR/iodoTyrRS-ed [Fig. 2(C)], in which the enzyme variant was expressed constitutively from the actin 5C promoter. S2 cells were then transfected with this plasmid, together with another plasmid carrying lacZ(Am91). Amber suppression with an efficiency of 12% was observed in the presence of 3-iodo-L-tyrosine [Fig. 2(D)]. When either the suppressor tRNA or iodoTyrRS-ed was removed from the plasmid, the amber suppression was hardly detectable, showing that both the prokaryotic tRNA and TyrRS were necessary for the suppression. In the absence of 3-iodo-L-tyrosine, the suppression efficiency was reduced from 12% to 0.4%, showing that iodoTyrRS-ed is specific for the non-natural amino acid, whose occupancy at the amber codon was estimated to be more than 95%.

Development of S2 cells stably maintaining the genetic system encoding 3-iodo-L-tyrosine

S2 cells have been stably transfected with recombinant genes to achieve the high-yield production of target proteins, because hundreds of copies of the expression cassette can be introduced into chromosomes, and the strong metallothionein promoter is available for the inducible expression of recombinant proteins.31 Therefore, we attempted to stably maintain the iodoTyrRS-ed and E. coli suppressor tRNATyr pair in S2 cells for alloprotein production. Since it is difficult to isolate a single S2 cell and grow it further, cells stably maintaining a certain plasmid can only be enriched in a polyclonal cell population. First, we created plasmids pIY-LacZWT and pIY-LacZ(Am91) by cloning the wild-type lacZ gene and the lacZ(Am91) gene, respectively, in a plasmid carrying the iodoTyrRS-ed gene and three copies of U6-EYR. All of the protein genes were placed under the control of the metallothionein promoter. To select cells stably maintaining these plasmids, S2 cells were also transfected with the plasmids harboring marker genes, in addition to the above plasmids. One of the markers was the constitutively expressed puromycin resistance (pac) gene, while the other was an amber mutant of the blasticidin S-resistance (bsr) gene, placed under the control of the methallothionein promoter. The selection was performed in two steps, using these antibiotics [Fig. 3(A)].

Figure 3. Enrichment of the stably transfected S2 cells. (A) Schematic illustration of the applied procedure. For details, refer to Materials and Methods section. (B–E) S2 cells harboring pIY-LacZ(Am91) (B, D) and pIY-LacZ (C, E) were stained with X-gal at the selection steps indicated in panel A. The percentage of stained cells is shown above each panel.

Download figure to PowerPoint

thumbnail image

S2 cells were incubated for 2 weeks in the presence of puromycin. After this first selection, 38% of the cells transfected with pIY-LacZ exhibited the β-galactosidase activity, as judged by X-gal staining, while 7% of the cells with pIY-LacZ(Am91) displayed the activity [Fig. 3(B,C)]. Provided that the fraction of cells actually transfected with the plasmid is similar between these two plasmids, the difference in the percentage of stained cells should mean that some of the cells harboring pIY-LacZ(Am91) could not support a detectable level of LacZ production, probably because the low-expression level of iodoTyrRS-ed or the suppressor tRNA. To enrich the cells with high-level amber suppression, we performed the second selection, which was dependent on the suppression of the amber mutant bsr gene.

The first trial of the second selection was performed by inducing the expression of iodoTyrRS-ed and the mutant bsr gene, with 3-iodo-L-tyrosine and blasticidin supplemented in the growth media. However, the cells exhibiting the β-galactosidase activity were not enriched, probably because even poor expression of the iodoTyrRS-ed–tRNATyr pair supported a sufficient expression of the mutant bsr gene for cell survival. Therefore, we decided to take advantage of the marginal level of suppression caused by the iodoTyrRS-ed–tRNA pair in the absence of non-natural amino acids. As described earlier, this pair introduced into S2 cells transiently caused the suppression at 0.4% efficiency without 3-iodo-L-tyrosine. Only the cells efficiently expressing the iodoTyrRS-ed–tRNA pair were expected to support the required expression level of the mutant bsr gene in the absence of 3-iodo-L-tyrosine.

After the second selection was performed by this modified procedure, 39% of the cells with pIY-LacZ(Am91), which survived for about 50 days after transfection, exhibited β-galactosidase activity in the presence of 3-iodo-L-tyrosine [Fig. 3(D)]. On the other hand, the cells with pIY-LacZ were also subjected to the second selection, and the population with the β-galactosidase activity significantly increased, from 38 to 60% [Fig. 3(E)]. This observation suggested that not every cell that had survived the puromycin selection harbored the pIY-LacZ plasmid, and that the population of the cells with pIY-LacZ was increased after the second selection, which required the activity of the iodoTyrRS-ed–tRNA pair.

Finally, we compared the alloprotein yields between the stably and transiently transformed S2 cells. The cell population enriched with the cells stably maintaining pIY-LacZ(Am91) was incubated for 3 days in the presence of 3-iodo-L-tyrosine, while the transiently transfected population was also incubated for 2 days with the non-natural amino acid. Cell extracts were prepared from 2 × 106 cells of each population, for the determination of the β-galactosidase activity. We found that the yield of the amber suppression product from the “stable cell” population was 14% of that from the “transient cell” population. By staining the stable cell population with X-gal, we found that the proportion of stably transformed cells dropped from 39% to 14%, during the subculturing process before alloprotein production. This drop in proportion occurred despite the supplementation of the growth medium with blasticidin. Subculturing is a necessary step to generate a cell population sufficient for the large-scale production of a recombinant protein, and a reduction in the proportion of stably transformed cells is often seen with S2 cells. It seems that this problem must be overcome to obtain a large amount of alloprotein from the stable cell population.

High-yield alloprotein production in S2 cells

We demonstrated the high-yield production of an alloprotein, using S2 cells transiently transfected with the plasmid pAcEYR/iodoTyrRS-ed [Fig. 2(C)]. We incorporated 3-iodo-L-tyrosine into human interleukin-8 (IL-8) at the amber position located just before the C-terminal tag sequence. The yield was 5 μg of the purified alloprotein per 2.4 mL cell culture, which demonstrated a high yield of alloprotein based on the transient transfection method [Fig. 4(A)]. We then incorporated another non-natural amino acid, 4-azido-L-phenylalanine (AzF), into proteins. This amino acid is available for site-specific protein modification, and can be incorporated by its specific variant of E. coli TyrRS,3 designated as AzFRS. The iodoTyrRS-ed gene in the plasmid was replaced by the gene encoding AzFRS. The full-length IL-8 was produced when AzF was present in the growth media, whereas the product was hardly detected without the non-natural amino acid [Fig. 4(B)]. The yield of the AzF-containing IL-8 was determined as 2.2 μg/2.4 mL cell culture, which was 4.5% of the yield of the wild-type IL-8. This alloprotein yield is essentially comparable to the yield that we previously achieved with human embryonic kidney 293 cells.12

Figure 4. Production of IL-8 variants containing 3-iodo-L-tyrosine and 4-azido-L-phenylalanine in S2 cells. (A, B) SDS-polyacrylamide electrophoresis of the purified IL-8 and its variants with the non-natural amino acids. Five- and 10-percent amounts of the obtained wild-type IL-8 were applied for comparison. The product of the amber mutant IL-8 gene was obtained in the presence of 3-iodo-L-tyrosine (+IY) and 4-azido-L-phenylalanine (+AzF), while it was scarcely obtained in the absence of these amino acids (–IY, –AzF). (C) A fluorescent image of the SDS-polyacrylamide gel of panel B, obtained with an LAS-1000 image analyzer (Fujifilm, Japan).

Download figure to PowerPoint

thumbnail image

Site-specific protein modification of the azido-containing IL-8 was performed by the Staudinger–Bertozzi reaction,32 using triarylphosphine conjugated with fluorescein.11 After the reaction with the fluorescent probe, the native IL-8 and the azido-containing variant were analyzed using a fluorescence imager, and only the band corresponding to the variant was observed [Fig. 4(C)]. Finally, we conducted mass spectrometric analyses before and after the labeling of the azido-containing IL-8 with a biotin-triarylphosphine conjugate. The mass spectrum before the reaction shows two major peaks, X and Y, corresponding to the IL-8 molecules with one 4-aminophenylalanine residue and with one AzF residue, respectively [Fig. 5(A)]. The amino group is probably derived from the azido group by degradation after translation. The two minor peaks, y1 and y2, corresponded to the phosphorylated and sugar-attached IL-8 variants with AzF, judging from their average mass. Thus, the mass spectrometric data revealed that the produced full-length IL-8 contained only AzF at the amber position. After the labeling reaction, the biotin-labeled IL-8 variant was detected as the major peak, Z, with its phosphorylated and sugar-attached derivatives in the minor peaks z1 and z2, respectively [Fig. 5(B)]. On the other hand, the AzF-containing IL-8 variant was found as a minor peak, showing that the majority of the azido-containing IL-8 was labeled in the Staudinger–Bertozzi reaction. The IL-8 with 4-aminophenylalanine was still detected, because it cannot react with the reagent.

Figure 5. MALDI-TOF analysis of the IL-8 derivatives before (A) and after (B) the labeling reaction with a triarylphosphine-biotin conjugate. The peaks X, Y, and Z correspond to the IL-8 molecules with 4-aminophenylalanine and AzF, and the biotin-labeled IL-8 molecule, respectively.

Download figure to PowerPoint

thumbnail image

Discussion

  1. Top of page
  2. Abstract
  3. Introduction
  4. Results
  5. Discussion
  6. Materials and Methods
  7. Acknowledgements
  8. References

In this study, we developed a D. melanogaster S2 cell-based system for producing proteins with non-natural amino acids at specific sites. This is the first report describing the genetic encoding of such amino acids in insect cells, although an insect cell-free translation system has been used to incorporate non-natural amino acids into proteins site-specifically.33 Three different gene constructs were designed, based on the factors known to be critical for the expression of a prokaryotic suppressor tRNA in eukaryotic cells. Although the B. stearothermophilus tRNATyr gene, with the upstream sequence of the fly tRNATyr gene, was able to function in S2 cells, the E. coli suppressor tRNATyr transcribed from the fly U6 promoter exhibited more efficient amber suppression. The introduction of multiple copies of the U6-tRNA gene increased the alloprotein yield, as also found in mammalian cells. On the other hand, the tandem gene construct consisting of the fly tRNATyr gene followed by the E. coli suppressor tRNATyr gene hardly worked in the insect cells, although a similar construct successfully expressed the prokaryotic tRNATyr to produce alloproteins in yeast cells.22 Yeasts naturally have tandem tRNA genes, and a yeast tRNA gene has been used to transcribe exogenous genes in yeast cells,34 whereas no tandem tRNA genes have been found in the fly.

The stable maintenance of a system to genetically encode non-natural amino acids in mammalian cells has not been achieved. Although an aaRS variant gene was stably maintained in Chinese hamster ovary cells, the paired suppressor tRNA was not stably expressed in the cells.2 This study demonstrated the feasibility of the stable maintenance of an aaRS–suppressor tRNA pair for a non-natural amino acid in S2 cells. Since the S2 cell line does not allow single-cell isolation, it is only feasible to enrich stably transfected cells in the polyclonal cell population. This drawback has two undesirable effects: it is difficult to increase the proportion of stably transfected cells to nearly 100%, and this proportion often drops during subculturing. Our selection procedure, which takes advantage of the amber suppression due to the introduced iodoTyrRS-ed and suppressor tRNATyr pair, enriched the stably transfected cells to 40% of the total. Although the transiently transfected cell population yielded a significantly larger amount of alloprotein, future improvements of the enriching and subculturing procedures will also make stably transfected cells useful for the high-yield production of alloproteins.

S2 cells have been used to produce chemokines, cytokines, and antibodies for both protein analyses and therapeutic purposes. The site-specific protein modification by the incorporation of the azido group can be utilized to add polyethylene glycol to proteins, to increase their stability for use as therapeutic agents.35 Antibodies may be labeled with a fluorescent probe at specific sites that do not interfere with antigen binding. We recently showed that the site-specific incorporation of 3-iodo-L-tyrosine facilitates protein X-ray crystallography,36 and this method can now be applied to proteins prepared with S2 cells. The incorporation of other useful non-natural amino acids besides tyrosine derivatives, as well as the use of other insect cell lines, such as Sf9 and HighFive, will be the targets of further study. Our achievement with S2 cells will facilitate the further development of alloprotein-producing systems with insect cells.

Materials and Methods

  1. Top of page
  2. Abstract
  3. Introduction
  4. Results
  5. Discussion
  6. Materials and Methods
  7. Acknowledgements
  8. References

Plasmids

Three prokaryotic tRNATyr genes were each constructed on the pCR4 Blunt-TOPO vector (Invitrogen). First, the D. melanogaster U6-2 promoter sequence was amplified by PCR from pDU62P30 and then linked to the 5′ end of the E. coli suppressor tRNATyr sequence, without the 3'-CCA trinucleotide,2 to create U6-EYR. Second, the sequence of the D. melanogaster tRNATyr gene from positions –123 to +73, with position +1 corresponding to the 5′ end of the tRNA,23 was obtained from S2 chromosomal DNA extracted using a yeast genome extraction kit, Dr. GenTLE (Takara, Japan), and was then placed upstream of the E. coli suppressor tRNATyr sequence with a 24-base linker sequence, AGATCTCATAAAAAACAAAAAAAT. Third, the 123-nucleotide upstream sequence of the D. melanogaster tRNATyr starting from position –1 was attached to the 5′ end of the B. stearothermophilus suppressor tRNATyr. The lacZ and amber mutant lacZ(Am91)37 genes were substituted for the lacZ gene in the pMT/V5-His/lacZ vector (Invitrogen), to create the plasmids pLacZ and pLacZ(Am91), respectively. The E. coli TyrRS variant iodoTyrRS-ed29 was cloned into the pMT/V5-HisA and pAc5.1/V5-HisA vectors (Invitrogen) to create pMT/iodoTyrRS-ed and pAc/iodoTyrRS-ed, respectively. The sequence encoding human IL-8 in the processed form (lacking the first 27 amino acids), capped by four amino acids (RYGG) and C-terminally tagged with a FLAG and a 6 × His sequence in this order, was cloned just after the BiP secretion signal (MKLCILLAVVAFVGLSLG) in the pAcBiP vector,38 to create pAcBiP/IL-8. An amber codon was inserted just before the FLAG tag in pAcBip/IL-8, to create pAcBip/IL-8(Am).

To construct the plasmids carrying the genes encoding the TyrRS variants, the suppressor tRNATyr, and the reporter LacZ, three copies of U6-EYR were cloned at the SalI sites of pMT and pAc5.1 to create pMTEYR and pAcEYR, respectively. The gene encoding iodoTyrRS-ed was cloned into pMTEYR and pAcEYR to create pMTEYR/iodoTyrRS-ed and pAcEYR/iodoTyrRS-ed, respectively, whereas the AzFRS gene was cloned into pAcEYR to create pAcEYR/AzFRS. The lacZ and lacZ(Am91) genes were cloned into the ScaI site of pMTEYR/iodoTyrRS-ed, to create pIY-LacZ and pIY-LacZ(Am91), respectively.

The blasticidin S-resistance gene was cloned into the pMT vector, and the 38th codon was then mutagenized to the amber codon to create pMT/bsr(Am). The amber suppression product of this mutant gene containing 3-iodotyrosine in E. coli cells retains its activity. The puromycin resistance gene with the copia promoter, obtained from pCoBlast (Invitrogen), was cloned into the pGL3 vector (Promega), to create the plasmid pCoPur. The puromycin resistance gene and the promoter, obtained from pCoPur, were cloned into the SalI site of the pMT/bsr(Am) to create pMT/bsr(Am)/pac.

Amber suppression in S2 cells

The Drosophila S2 cells (Invitrogen) were cultured in Schneider's Drosophila medium (Invitrogen) containing 10% fetal bovine serum. Plasmid transfection was performed using 24- or 6-well plates. The following details in the transfection procedure refer to the use of a 24-well plate; fourfold larger amounts of cells and reagents were used with a 6-well plate. First, 0.5 × 106 cells in 0.5 mL of the growth medium were seeded in each well of a 24-well plate at 27°C for 24 h before transfection using Effectene (Qiagen). The plasmids (0.5 μg in total) were gently dissolved using a Vortex mixer for 1 s in EC buffer (75 μL) supplemented with the enhancer (8 μL), both from Qiagen, and this plasmid solution was incubated at room temperature for 5 min. The solution was mixed with 20 μL of Effectene by gently vortexing for 10 s, and was then incubated at room temperature for 15 min. The Effectene-plasmid solution was mixed with 125 μL of fresh medium for addition to the cells in each well, just after the growth medium in the well was replaced with 375 μL of fresh medium. After 2-h incubation, the growth medium was supplemented with penicillin, streptomycin, and non-natural amino acids. As a supplement in the medium, 3-iodo-L-tyrosine (Sigma) was dissolved in 0.1% acetic acid to a final concentration of 20 mM. 4-Azido-L-phenylalanine (Bachem) was dissolved in 0.2N HCl and then neutralized with 10N KOH, to prepare a solution with a final concentration of 10 mM. To induce the expression from the metallothionein promoter, a CuSO4 solution (100 mM) was added to the growth media to a final concentration of 500 μM. The β-galactosidase assay was performed as described.37 The X-gal staining of S2 cells was performed using a beta-galactosidase staining kit (Mirus Bio LLC, Madison, WI). The produced human IL-8 was purified from the recovered media by the batch method using Ni-Sepharose 6 fast flow (GE Healthcare). The Staudinger–Bertozzi reaction was performed as described previously.11

Stable transfection

The S2 cell culture (5 × 106 cells), in 5 mL of growth medium, was transfected with pCoPur and pMT/bsr(Am)/pac and either pIY-LacZ(Am91) or pIY-LacZWT, at a weight ratio of 1:1:19, respectively, with a total plasmid amount of 5.25 μg. After an incubation for 4 days at 27°C, the cells were collected by centrifugation to completely remove the old growth medium, which was replaced by fresh medium containing 10 μg/mL puromycin (Invitrogen). When the number of cells increased and some of them were found floating in the medium, the cell culture was diluted with fresh medium containing puromycin (10 μg/mL). After further incubation for 2 weeks with further dilutions by the puromycin-containing media, the CuSO4 solution was added to induce the expression of the amber mutant bsr gene and iodoTyrRS-ed, but 3-iodo-L-tyrosine was not supplemented in the medium at this stage. After 3 or 4 days, blasticidin S (Invivogen) was added to the cell culture at a final concentration of 25 μg/mL. When the medium became crowded with growing cells, the culture was diluted eightfold with medium lacking blasticidin S, for a healing cycle for 3 or 4 days, followed by an induction with CuSO4 for 3 or 4 days. The blasticidin selection and healing cycle were repeated one more time before cell staining with X-gal, or three more times before the β-gal assay.

Labeling reaction and mass spectrometric analysis

The Staudinger–Bertozzi reaction was performed according to the procedure previously described.11 Triarylphosphine-fluorescein and triarylphosphine-biotin conjugates were purchased from Shinsei Chemical Company Ltd. (Osaka, Japan). Mass spectrometric analysis was commercially performed by Shimadzu Biotech (Japan). IL-8 molecules in the labeling reaction mixture were treated with a Zip Tip pipette tip (Millipore) before the analysis.

Acknowledgements

  1. Top of page
  2. Abstract
  3. Introduction
  4. Results
  5. Discussion
  6. Materials and Methods
  7. Acknowledgements
  8. References

The authors thank Azusa Ishii and Tomoyo Nakayama for clerical assistance.

References

  1. Top of page
  2. Abstract
  3. Introduction
  4. Results
  5. Discussion
  6. Materials and Methods
  7. Acknowledgements
  8. References
  • 1
    Wang L, Brock A, Herberich B, Schultz PG ( 2001) Expanding the genetic code of Escherichia coli. Science 292: 498500.
  • 2
    Sakamoto K, Hayashi A, Sakamoto A, Kiga D, Nakayama H, Soma A, Kobayashi T, Kitabatake M, Takio K, Saito K, Shirouzu M, Hirao I, Yokoyama S ( 2002) Site-specific incorporation of an unnatural amino acid into proteins in mammalian cells. Nucleic Acids Res 30: 46924699.
  • 3
    Chin JW, Cropp TA, Anderson JC, Mukherji M, Zhang Z, Schultz PG ( 2003) An expanded eukaryotic genetic code. Science 301: 964967.
  • 4
    Koide H, Yokoyama S, Kawai G, Ha JM, Oka T, Kawai S, Miyake T, Fuwa T, Miyazawa T ( 1988) Biosynthesis of a protein containing a nonprotein amino acid by Escherichia coli: L-2-aminohexanoic acid at position 21 in human epidermal growth factor. Proc Natl Acad Sci USA 85: 62376241.
  • 5
    Xie J, Wang L, Wu N, Brock A, Spraggon G, Schultz PG ( 2006) The site-specific incorporation of p-iodo-L-phenylalanine into proteins for structure determination. Nat Biotechnol 22: 12971301.
  • 6
    Summerer D, Chen S, Wu N, Deiters A, Chin JW, Schultz PG ( 2006) A genetically encoded fluorescent amino acid. Proc Natl Acad Sci USA 103: 97859789.
  • 7
    Chin JW, Martin AB, King DS, Wang L, Schultz PG ( 2002) Addition of a photocrosslinking amino acid to the genetic code of Escherichia coli. Proc Natl Acad Sci USA 99: 1102011024.
  • 8
    Tippmann EM, Liu W, Summerer D, Mack AV, Schultz PG ( 2007) A genetically encoded diazirine photocrosslinker in Escherichia coli. ChemBioChem 8: 22102214.
  • 9
    Zhang Z, Smith BA, Wang L, Brock A, Cho C, Schultz PG ( 2003) A new strategy for the site-specific modification of proteins in vivo. Biochemistry 42: 67356746.
  • 10
    Chin JW, Santoro SW, Martin AB, King DS, Wang L, Schultz PG ( 2002) Addition of p-azido-L-phenylalanine to the genetic code of Escherichia coli. J Am Chem Soc 124: 90269027.
  • 11
    Yanagisawa T, Ishii R, Fukunaga R, Kobayashi T, Sakamoto K, Yokoyama S ( 2008) Multistep engineering of pyrrolysyl-tRNA synthetase to genetically encode N(epsilon)-(o-azidobenzyloxycarbonyl) lysine for site-specific protein modification. Chem Biol 15: 11871197.
  • 12
    Mukai T, Kobayashi T, Hino N, Yanagisawa T, Sakamoto K, Yokoyama S ( 2008) Adding l-lysine derivatives to the genetic code of mammalian cells with engineered pyrrolysyl-tRNA synthetases. Biochem Biophys Res Commun 371: 818822.
  • 13
    Guo J, Wang J, Anderson JC, Schultz PG ( 2008) Addition of an alpha-hydroxy acid to the genetic code of bacteria. Angew Chem Int Ed Engl 47: 722725.
  • 14
    Kobayashi T, Yanagisawa T, Sakamoto K, Yokoyama S ( 2009) Recognition of non-alpha-amino substrates by pyrrolysyl-tRNA synthetase. J Mol Biol 385: 13521360.
  • 15
    Liu CC, Schultz PG ( 2006) Recombinant expression of selectively sulfated proteins in Escherichia coli. Nat Biotechnol 24: 14361440.
  • 16
    Neumann H, Peak-Chew SY, Chin JW ( 2008) Genetically encoding N(epsilon)-acetyllysine in recombinant proteins. Nat Chem Biol 4: 232234.
  • 17
    Aloia AL, Glatz RV, McMurchie EJ, Leifert WR ( 2009) GPCR expression using baculovirus-infected Sf9 cells. Methods Mol Biol 552: 115129.
  • 18
    Johanson K, Appelbaum E, Doyle M, Hensley P, Zhao B, Abdel-Meguid SS, Young P, Cook R, Carr S, Matico R, Cusimano D, Dul E, Angelichio M, Brooks I, Winborne E, McDonnell P, Morton T, Bennett D, Sokoloski T, McNulty D, Rosenberg M, Chaiken I ( 1995) Binding interactions of human interleukin 5 with its receptor alpha subunit. Large scale production, structural, and functional studies of Drosophila-expressed recombinant proteins. J Biol Chem 270: 94599471.
  • 19
    Kirkpatrick RB, Ganguly S, Angelichio M, Griego S, Shatzman A, Silverman C, Rosenberg M ( 1995) Heavy chain dimers as well as complete antibodies are efficiently formed and secreted from Drosophila via a BiP-mediated pathway. J Biol Chem 270: 1980019805.
  • 20
    Drabkin HJ, Park HJ, RajBhandary UL ( 1996) Amber suppression in mammalian cells dependent upon expression of an Escherichia coli aminoacyl-tRNA synthetase gene. Mol Cell Biol 16: 907913.
  • 21
    Wang W, Takimoto JK, Louie GV, Baiga TJ, Noel JP, Lee KF, Slesinger PA, Wang L ( 2007) Genetically encoding unnatural amino acids for cellular and neuronal studies. Nat Neurosci 10: 10631072.
  • 22
    Wang Q, Wang L ( 2008) New methods enabling efficient incorporation of unnatural amino acids in yeast. J Am Chem Soc 130: 60666067.
  • 23
    Laski FA, Ganguly S, Sharp PA, RajBhandary UL, Rubin GM ( 1989) Construction, stable transformation, and function of an amber suppressor tRNA gene in Drosophila melanogaster. Proc Natl Acad Sci USA 86: 66966698.
  • 24
    Garza D, Medhora MM, Hartl DL ( 1990) Drosophila nonsense suppressors: functional analysis in Saccharomyces cerevisiae, Drosophila tissue culture cells and Drosophila melanogaster. Genetics 126: 625637.
  • 25
    Molnar CM, Reece T, Williams JA, Bell JB ( 1988) Transformation of Drosophila melanogaster with a suppressor tRNA gene (Sup3e tRNA(SerUGA)) from Schizosaccharomyces pombe. Genome 30: 211217.
  • 26
    Liu W, Brock A, Chen S, Chen S, Schultz PG ( 2007) Genetic incorporation of unnatural amino acids into proteins in mammalian cells. Nat Methods 4: 239244.
  • 27
    Ye S, Köhrer C, Huber T, Kazmi M, Sachdev P, Yan EC, Bhagat A, RajBhandary UL, Sakmar TP ( 2008) Site-specific incorporation of keto amino acids into functional G protein-coupled receptors using unnatural amino acid mutagenesis. J Biol Chem 283: 15251533.
  • 28
    Kiga D, Sakamoto K, Kodama K, Kigawa T, Matsuda T, Yabuki T, Shirouzu M, Harada Y, Nakayama H, Takio K, Hasegawa Y, Endo Y, Hirao I, Yokoyama S ( 2002) An engineered Escherichia coli tyrosyl-tRNA synthetase for site-specific incorporation of an unnatural amino acid into proteins in eukaryotic translation and its application in a wheat germ cell-free system. Proc Natl Acad Sci USA 99: 97159720.
  • 29
    Oki K, Sakamoto K, Kobayashi T, Sasaki HM, Yokoyama S ( 2008) Transplantation of a tyrosine editing domain into a tyrosyl-tRNA synthetase variant enhances its specificity for a tyrosine analog. Proc Natl Acad Sci USA 105: 1329813303.
  • 30
    Wakiyama M, Matsumoto T, Yokoyama S ( 2005) Drosophila U6 promoter-driven short hairpin RNAs effectively induce RNA interference in Schneider 2 cells. Biochem Biophys Res Commun 331: 11631170.
  • 31
    Johansen H, van der Straten A, Sweet R, Otto E, Maroni G, Rosenberg M ( 1989) Regulated expression at high copy number allows production of a growth-inhibitory oncogene product in Drosophila Schneider cells. Genes Dev 3: 882889.
  • 32
    Saxon E, Bertozzi CR ( 2000) Cell surface engineering by a modified Staudinger reaction. Science 287: 20072010.
  • 33
    Taki M, Tokuda Y, Ohtsuki T, Sisido M ( 2006) Design of carrier tRNAs and selection of four-base codons for efficient incorporation of various nonnatural amino acids into proteins in Spodoptera frugiperda 21 (Sf21) insect cell-free translation system. J Biosci Bioeng 102: 511517.
  • 34
    Otter CA, Edqvist J, Stråby KB ( 1992) Characterization of transcription and processing from plasmids that use polIII and a yeast tRNA gene as promoter to transcribe promoter-deficient downstream DNA. Biochim Biophys Acta 1131: 6268.
  • 35
    Deiters A, Cropp TA, Summerer D, Mukherji M, Schultz PG ( 2004) Site-specific PEGylation of proteins containing unnatural amino acids. Bioorg Med Chem Lett 14: 57435745.
  • 36
    Sakamoto K, Murayama K, Oki K, Iraha F, Kato-Murayama M, Takahashi M, Ohtake K, Kobayashi T, Kuramitsu S, Shirouzu M, Yokoyama S ( 2009) Genetic encoding of 3-iodo-L-tyrosine in Escherichia coli for single-wavelength anomalous dispersion phasing in protein crystallography. Structure 17: 335344.
  • 37
    Hino N, Hayashi A, Sakamoto K, Yokoyama S ( 2006) Site-specific incorporation of non-natural amino acids into proteins in mammalian cells with an expanded genetic code. Nat Protoc 1: 29572962.
  • 38
    Hara-Yokoyama M, Kimura T, Kaku H, Wakiyama M, Kaitsu Y, Inoue M, Kusano S, Shirouzu M, Yokoyama S, Katada T, Hirabayashi Y, Takatsu K, Yanagishita M ( 2008) Alteration of enzymatic properties of cell-surface antigen CD38 by agonistic anti-CD38 antibodies that prolong B cell survival and induce activation. Int Immunopharmacol 8: 5970.